AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
AC Immune announced three data presentations at the Alzheimer's Association International Conference (AAIC) 2026, focusing on its Morphomer-based pipeline for neurodegenerative diseases. The company will showcase early human imaging data for the first-in-class TDP-43 PET tracer [18F]ACI-19626 and Phase 1 results for the NLRP3 inhibitor ACI-19764.
Key figures
- Phase Of Trial
- Phase 1
- Potential milestone payments usd
- >$4.5 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.